JW Pharmaceutical announced on the 24th that it has launched a 100-tablet bottle packaging product of 'Rivarozet,' an improved new drug with a combination of ingredients for dyslipidemia (hyperlipidemia).
Rivarozet is the world's first improved combination new drug that combines pitavastatin, a statin class drug, and ezetimibe, a cholesterol absorption inhibitor. It has been steadily growing in the domestic market due to its excellent cholesterol-lowering effect and safety, and it is highly utilized in various combination therapies.
Previously supplied only in 30-tablet PTP (Press Through Pack) packaging, the addition of the 100-tablet bottle packaging allows patients to take the medication more conveniently and improves the dispensing process at hospitals and pharmacies, thereby enhancing practical convenience in medical settings, according to the company.
PTP packaging is suitable for portability and short-term use, with the advantage of being able to take one pill at a time separately. On the other hand, bottle packaging is preferred in hospitals and pharmacies because it offers higher dispensing efficiency for patients taking multiple medications or for long-term prescriptions.
A JW Pharmaceutical official stated, "Rivarozet is the only pitavastatin-ezetimibe combination treatment that offers both PTP and bottle packaging, further strengthening the product's competitiveness," adding, "We will continue efforts to enhance ease of use and customer satisfaction by reflecting the diverse needs of medical settings."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
